Lantheus Holdings’ 10% owner, Lantheus Alpha Therapy, sold 247,932 shares across two transactions at $3.11 to $3.15 per share. The owner retained 11,273,364 shares after the sales, meaning the transaction represented about 2.2% of its resulting holding and gives investors a precise view of the remaining position.
Key Highlights
- The transactions took place on September 3 and September 4, 2026.
- Lantheus Alpha Therapy owned 11,273,364 shares after the sales.
- Both transactions carried the SEC sale code S.
Lantheus Holdings, Inc. (NASDAQ: LNTH) saw its 10% owner sell 247,932 shares across two transactions at prices ranging from $3.11 to $3.15 per share. The sales involved Lantheus Alpha Therapy, LLC, which owned 11,273,364 shares after the transactions.
and September 4 Lantheus Alpha Therapy completed the sales on September 3 and September 4, 2026. Both transactions were classified with the code S. The reported prices ranged from $3.11 to $3.15 per share, and the total transaction covered 247,932 shares. The transaction details identify Perspective Therapeutics, Inc (AMEX: CATX). as the stock involved.
FAQs
Q: How many shares did Lantheus Alpha Therapy sell?
A: Lantheus Alpha Therapy sold 247,932 shares of Perspective Therapeutics, Inc. across two separate transactions. The reported sale prices ranged from $3.11 to $3.15 per share.
Q: What happened to LNTH stock ownership after the sale?
A: Lantheus Alpha Therapy owned 11,273,364 shares after the transactions. It is identified as a 10% owner of Lantheus Holdings, Inc.
Q: When did the Lantheus Alpha Therapy share sales occur?
A: Lantheus Alpha Therapy completed the two share sales on September 3 and September 4, 2026. Both transactions were classified under sale code S.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.